Skip to main content
TipRanks
Go Ultimate75% OFF

CellSeed Inc. (7776) AI Stock Analysis

0 Followers
JP:7776

CellSeed Inc.

(TSE/TYO:7776)

Select Model
Rating:26Underperform
Price Target:JPY 136.00â–¼(-4.23% Downside)
Action:reiterated
Date:09/06/26

The score is driven primarily by severe financial weakness: a 56.7% revenue decline, widening ¥1.1 billion net loss, and roughly ¥1 billion of annual cash burn that is rapidly eroding an equity base already down from ¥2.16 billion to ¥1.27 billion, raising the likelihood of a dilutive capital raise. Low leverage (debt-to-equity of 10.5%) provides only partial offset. Technicals reinforce the caution, with the price below all major moving averages and negative MACD. Valuation provides no support given negative earnings and no dividend. Earnings call and corporate event components were excluded due to lack of data, with their weight redistributed to the remaining factors.

Positive Factors
Conservative LeverageConservative leverage gives CellSeed greater financial flexibility than a highly indebted biotechnology company. Low debt reduces fixed repayment pressure and may leave more capacity to fund research, partnerships, or commercialization efforts while the company works toward improving profitability.
Negative Factors
Sharp Revenue ContractionThe sharp 2025 revenue decline shows that recent commercial traction has weakened materially. A smaller revenue base makes it harder to absorb research and operating expenses, increases dependence on future product or service wins, and raises uncertainty around the timing of any sustainable recovery.

CellSeed Inc. (7776) vs. iShares MSCI Japan ETF (EWJ)

-60%-40%-20%0%20%40%JP:7776-51.70%EWJ+6.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 5.63B
Dividend Yield
―
Average Volume (3M)
194.07K
Price to Earnings (P/E)
-4.6
Beta (1Y)
1.31
Revenue Growth
-49.43%
EPS Growth
-3.77%
Country
Japan
Employees
36
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

CellSeed Inc. Business Overview & Revenue Model

Company Description

CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass ep...

CellSeed Inc. Financial Statement Overview

Summary

Financials are very weak. Revenue collapsed 56.7% to ¥83.7 million in 2025 while net losses widened to ¥1.1 billion, with operating losses exceeding 12x revenue (Income Statement score 15). Cash flow is the most critical concern: operating cash flow of -¥989 million and free cash flow of -¥1.02 billion, extending a multi-year burn exceeding ¥4 billion (Cash Flow score 12). The balance sheet is the only relative bright spot, with low debt-to-equity of 10.5% and ¥1.27 billion of equity, but that equity fell sharply from ¥2.16 billion and ROE is -87%, implying possible capital-raise needs within 1-2 years (Balance Sheet score 42).

Income Statement

15Very Negative

Balance Sheet

42Neutral

Cash Flow

12Very Negative
Financial statement breakdown
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue83.68M193.28M190.13M126.43M161.67M
Gross Profit42.75M110.11M107.16M61.02M84.04M
EBITDA-1.05B-855.49M-836.52M-750.00M-905.67M
Net Income-1.10B-859.84M-846.53M-759.68M-912.87M
Balance Sheet
Total Assets1.66B2.43B2.47B1.54B1.41B
Cash, Cash Equivalents and Short-Term Investments1.32B2.13B2.16B1.07B846.67M
Total Debt132.92M143.75M151.25M158.75M160.00M
Total Liabilities387.46M269.88M301.05M365.58M363.58M
Stockholders Equity1.27B2.16B2.16B1.18B1.04B
Cash Flow
Free Cash Flow-1.02B-884.47M-801.07M-733.60M-908.15M
Operating Cash Flow-988.98M-866.10M-779.43M-718.01M-817.15M
Investing Cash Flow-26.72M-18.37M56.31M61.73M-110.44M
Financing Cash Flow200.30M855.48M1.81B881.81M396.88M

CellSeed Inc. Technical Analysis

Technical Analysis SentimentNegative
Last Price142.00

Price Trends

50DMA198.46Negative
100DMA211.05Negative
200DMA247.94Negative

Market Momentum

MACD-13.88Positive
RSI21.80Positive
STOCH14.78Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7776, the sentiment is Negative. The current price of 142.00 is below the 20-day moving average (MA) of 172.75, below the 50-day MA of 198.46, and below the 200-day MA of 247.94, indicating a bearish trend. The MACD of -13.88 indicates Positive momentum. The RSI at 21.80 is Positive, neither overbought nor oversold. The STOCH value of 14.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7776.

CellSeed Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:7776 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:7096JP:709661NeutralJPY 6.56B55.76――2.55%-43.06%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4978JP:497845NeutralJPY 11.75B-24.14――-8.23%-48.10%
JP:7774JP:777442NeutralJPY 26.03B-70.06――17.05%10.47%
JP:4599JP:459939UnderperformJPY 7.77B-4.11―――4.85%
JP:4593JP:459337UnderperformJPY 28.46B-11.95――-51.55%52.19%
JP:7776JP:777626UnderperformJPY 6.07B-4.61――-49.43%-3.77%

* Healthcare Sector Average

Performance Comparison

-50%0%50%JP:7776JP:4593JP:4599JP:4978JP:7096JP:7774Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:7776 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:7776CellSeed Inc.142.00-152.00-51.70%
JP:4593Healios KK198.00-269.00-57.60%
JP:4599StemRIM Inc.122.00-157.00-56.27%
JP:4978ReproCELL Inc.105.00-50.00-32.26%
JP:7096StemCell Institute620.00-147.00-19.17%
JP:7774Japan Tissue Engineering Co., Ltd.620.00134.0027.57%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026